From Guidelines to Practice: Clinical Perspectives on Mitomycin-Based Chemoradiation for Anal Cancer
Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and mitomycin with radiation, which remains the preferred treatment approach despite alternative options like capecitabine, with modifications including day 28 mitomycin based on subsequent studies showing improved colostomy-free survival.
Evolution of Treatment Protocols
The treatment evolution for anal cancer began in the 1970s with the Nigro regimen, combining 5-fluorouracil and mitomycin with radiation therapy, which demonstrated the potential to spare surgery through chemoradiation alone. This landmark study showed 79% complete clinical response rates in locally advanced disease, with pathological complete responses in patients who underwent subsequent surgery. The regimen established chemoradiation as the definitive treatment approach for locally advanced anal cancer.
Recent advances include the 2019 InterAACT study, a phase 2 trial comparing carboplatin/paclitaxel vs 5-FU/cisplatin in metastatic disease, showing improved progression-free survival and tolerability with the carboplatin regimen. The most significant development is the 2025 PODIUM-303 study, the first large phase 3 global trial incorporating checkpoint inhibitors with chemotherapy in metastatic anal cancer, representing a paradigm shift toward immunotherapy integration.
Current NCCN guidelines recommend the Nigro regimen (5-FU and mitomycin with radiation) as the preferred approach for locally advanced disease, with capecitabine as an alternative to 5-FU based on smaller studies and retrospective analyses. The evolution from 3-week radiation protocols to modern intensity-modulated radiation therapy techniques delivering 70 Gy over 6 weeks has improved treatment precision and outcomes while maintaining the core chemotherapy backbone established decades earlier.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
